For­bion rais­es $316M to tap the po­ten­tial of Eu­ro­pean biotech plays

Where­as there’s no lack of ven­ture dol­lars for US biotechs these days, their Eu­ro­pean coun­ter­parts are still deal­ing with an “on­go­ing un­der­sup­ply” of cap­i­tal — at least ac­cord­ing to the Eu­rope-based VCs at For­bion Cap­i­tal. And they are ad­dress­ing the prob­lem head-on with $316 mil­lion (€270 mil­lion) they just raised.

Sander Slootweg

Mark­ing the first close of its fourth fund — which had an orig­i­nal tar­get of $292 mil­lion (€250 mil­lion) — the mon­ey from new and ex­ist­ing in­vestors will al­low the firm to bet on around 15 com­pa­nies with a hands-on ap­proach. The ide­al port­fo­lio will fea­ture five com­pa­nies built from scratch at For­bion (“build” op­por­tu­ni­ties) and 10 oth­ers that it thinks it can help trans­form in­to high-re­turn busi­ness­es (“growth” op­por­tu­ni­ties).
In most cas­es, that will mean com­mand­ing a lead po­si­tion in the biotech com­pa­nies — any­where from 20% to 50% — and work­ing close­ly with the founders, just as they have done in their $200 mil­lion-plus For­bion III.

This is the third Eu­ro­pean biotech ven­ture fund to land to­day, to­tal­ing more than $900 mil­lion.

If For­bion learn any­thing from their last fund, it is that “(bio)phar­ma is the most lu­cra­tive sec­tor in life sci­ences. Com­pa­nies with nov­el prod­ucts and tech­nolo­gies get ac­quired ear­ly on and pub­lic mar­kets have been very re­cep­tive,” says Sander Slootweg, who has been tapped to man­age the fund with Geert-Jan Mul­der and Mar­tien van Osch.

Mar­tien von Osch

While the fund is ex­plic­it­ly Eu­ro­cen­tric, 20% of For­bion IV will be al­lo­cat­ed to North Amer­i­can busi­ness­es.

Slootweg sees the Eu­ro­pean biotech scene as “very healthy,” with on­ly pub­lic mar­kets lag­ging some­what be­hind the US — which isn’t re­al­ly that much of a prob­lem when you con­sid­er the rel­a­tive ease for for­eign is­suers to list on the Nas­daq.

He would know. Of the com­pa­nies For­bion wa­gered on in its last run, brain dis­or­der drug­mak­er Prex­ton Ther­a­peu­tics was sold to Lund­beck for $1.1 bil­lion (€905 mil­lion); NASH play­er Arkar­na was picked up by Al­ler­gan with a $50 mil­lion up­front; I/O biotech Rigontec was ac­quired by Mer­ck for $554 mil­lion (€463 mil­lion); and an­oth­er I/O start­up, Replimune, re­cent­ly joined the US biotech IPO fi­es­ta, rais­ing $100 mil­lion.

Geert-Jan Mul­der

We will have to wait un­til this fall, when For­bion aims to close the fund, to learn more about the in­vest­ments that they ul­ti­mate­ly de­cide to go with. But the team has al­ready iden­ti­fied quite a few of them, span­ning ar­eas such as the mi­cro­bio­me, in­flam­ma­tion, car­dio­vas­cu­lar and meta­bol­ic dis­ease, Slootweg tells me.

Martin Shkreli [via Getty]

Pris­on­er #87850-053 does not get to add drug de­vel­op­er to his list of cred­its

Just days after Retrophin shed its last ties to founder Martin Shkreli, the biotech is reporting that the lead drug he co-invented flopped in a pivotal trial. Fosmetpantotenate flunked both the primary and key secondary endpoints in a placebo-controlled trial for a rare disease called pantothenate kinase-associated neurodegeneration, or PKAN.

Endpoints News

Basic subscription required

Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.

We­bi­nar: Re­al World End­points — the brave new world com­ing in build­ing fran­chise ther­a­pies

Several biopharma companies have been working on expanding drug labels through the use of real world endpoints, combing through the data to find evidence of a drug’s efficacy for particular indications. But we’ve just begun. Real World Evidence is becoming an important part of every clinical development plan, in the soup-through-nuts approach used in building franchises.

I’ve recruited a panel of 3 top experts in the field — the first in a series of premium webinars — to look at the practical realities governing what can be done today, and where this is headed over the next few years, at the prodding of the FDA.

ZHEN SU — Merck Serono’s Senior Vice President and Global Head of Oncology
ELLIOTT LEVY — Amgen’s Senior Vice President of Global Development
CHRIS BOSHOFF — Pfizer Oncology’s Chief Development Officer

A premium subscription to Endpoints News is required to attend this webinar. Please upgrade to either an Insider or Enterprise plan for access. Already have Endpoints Premium? Please sign-in below. You can contact our Subscriptions team at help@endpointsnews.com with any issues.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Hal Barron. GSK

GSK's Hal Bar­ron her­alds their sec­ond pos­i­tive piv­otal for cru­cial an­ti-BC­MA ther­a­py, point­ing to a push for quick OKs in a crowd­ed field

Hal Barron has his second positive round of Phase III data in hand for his anti-BCMA antibody drug conjugate belantamab mafodotin (GSK2857916). And GSK’s research chief says the data paves the way for their drive in search of an FDA approval for treating multiple myeloma.

It’s hard to overestimate the importance of this drug for GSK, a cornerstone of Barron’s campaign to make a dramatic impact on the oncology market and provide some long-lost excitement for the pharma giant’s pipeline. They’re putting this BCMA program at the front of that charge — looking to lead a host of rivals all aimed at the same target.

We don’t know what the data are yet, but DREAMM-2 falls on the heels of a promising set of data delivered 5 months ago for DREAMM-1. There investigators noted that complete responses among treatment-resistant patients rose to 15% in the extra year’s worth of data to look over, with a median progression-free survival rate of 12 months, up from 7.9 months reported earlier. The median duration of response was 14.3 months.

Endpoints News

Basic subscription required

Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: An em­bold­ened As­traZeneca splurges $95M on a pri­or­i­ty re­view vouch­er. Where do they need the FDA to hus­tle up?

AstraZeneca is in a hurry.

We learned this morning that the pharma giant — not known as a big spender, until recently — forked over $95 million to get its hands on a priority review voucher from Sobi, otherwise known as Swedish Orphan Biovitrum.

That marks another step down on price for a PRV, which allows the holder to slash 4 months off of any FDA review time.

Endpoints News

Basic subscription required

Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.

Brian Kaspar. AveXis via Twitter

AveX­is sci­en­tif­ic founder fires back at No­var­tis CEO Vas Narasimhan, 'cat­e­gor­i­cal­ly de­nies any wrong­do­ing'

Brian Kaspar’s head was among the first to roll at Novartis after company execs became aware of the fact that manipulated data had been included in its application for Zolgensma, now the world’s most expensive therapy.

But in his first public response, the scientific founder at AveXis — acquired by Novartis for $8.7 billion — is firing back. And he says that not only was he not involved in any wrongdoing, he’s ready to defend his name as needed.

I reached out to Brian Kaspar after Novartis put out word that he and his brother Allen had been axed in mid-May, two months after the company became aware of the allegations related to manipulated data. His response came back through his attorneys.

Endpoints News

Basic subscription required

Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.

Why would Am­gen want to buy Alex­ion? An­a­lysts call hot­ly ru­mored takeover un­like­ly, but seize the mo­ment

A rumor that Amgen is closing in on buyout deal for Alexion has sparked a guessing game on just what kind of M&A strategy Amgen is pursuing and how much Alexion is worth.

Mizuho analyst Salim Syed first lent credence to the report out of the Spanish news outlet Intereconomía, which said Amgen is bidding as much as $200 per share. While the source may be questionable, “the concept of this happening doesn’t sound too crazy to me,” he wrote.

FDA asks why No­var­tis took two months to launch for­mal in­ter­nal probe, af­ter AveX­is flagged da­ta ma­nip­u­la­tion

And the plot thickens. Novartis $NVS officials are reportedly now scrambling to explain to the FDA why it took them two months to open an internal investigation into data discrepancies for their $2.1 million gene-therapy for spinal muscular dystrophy — the world’s most expensive drug.

Endpoints News

Basic subscription required

Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.

Build­ing on suc­cess­ful PD-1 pact, Eli Lil­ly li­cens­es di­a­betes drug to Chi­nese part­ners at In­novent

Eli Lilly is expanding its partnership with China’s Innovent in a deal involving a diabetes drug sitting in its Phase I reserves.

The two companies had jointly developed one of China’s first homegrown PD-1 agents, scoring an approval for Tyvyt (sintilimab) late last year for relapsed/refractory classical Hodgkin’s lymphoma. This time around, Lilly is out-licensing a piece of its diabetes pipeline, a leading franchise that has historically produced the top-selling Trulicity and Humalog.

Am­gen, Al­ler­gan biosim­i­lar of Roche's block­buster Rit­ux­an clears an­oth­er US piv­otal study 

Novartis $NVS may have given up, but Amgen $AMGN and Allergan $AGN are plowing ahead with their knockoff of Roche’s blockbuster biologic Rituxan in the United States.

Their copycat, ABP 798, was found to have a clinically equivalent impact as Rituxan — meeting the main goal of the study involving CD20-positive B-cell non-Hodgkin’s lymphoma patients. This is the second trial supporting the profile of the biosimilar. In January, it came through with positive PK results in patients with rheumatoid arthritis.